NanoViricides Submits Orphan Drug Application for NV-387 Measles Treatment as Cases Surge in US
核心洞察
NanoViricides submitted an Orphan Drug Designation application to the FDA for NV-387, a nanomedicine-based treatment for measles (搜索), amid rising case numbers in the United States.
The company reported 2,251 measles (搜索) cases and three deaths in 2025, representing a significant increase from 59 cases in previous years, highlighting the urgent medical need.
If approved, the orphan drug designation would provide NanoViricides with tax credits, fee exemptions, and up to seven years of market exclusivity for NV-387.
NanoViricides, Inc. (NYSE American: NNVC) has submitted an Orphan Drug Designation (ODD) application to the US FDA Office of Orphan Products Development for NV-387, a nanomedicine-based treatment for measles (搜索), as the United States faces a concerning surge in measles cases.
The clinical-stage biotechnology company announced that 2,251 measles (搜索) cases and three deaths were recorded in 2025, representing a dramatic increase from 59 cases in previous years and 285 cases in the year prior. This escalation underscores the critical need for effective measles treatments, as no approved therapies currently exist for the viral infection.
Orphan Drug Strategy and Regulatory Pathway
NanoViricides partnered with regulatory consultant Only Orphans Cote (搜索), LLC, founded by Dr. Timothy Cote, through a Master Services Agreement to develop the company's orphan drug strategy for NV-387. The collaboration will focus on preparing and prosecuting orphan drug designation applications at the US FDA Office of Orphan Products.
If granted orphan drug status, NV-387 would qualify for significant regulatory incentives including tax credits, user-fee exemptions, and up to seven years of market exclusivity. These benefits are designed to encourage development of treatments for rare diseases affecting fewer than 200,000 patients in the United States.
Broad-Spectrum Antiviral Platform
NV-387 represents NanoViricides' lead drug candidate in its broad-spectrum antiviral portfolio based on host-mimetic nanomedicine technology. The compound has demonstrated strong activity in lethal animal models of orthopoxvirus (搜索) infections, supporting its potential for multiple orphan designations including smallpox (搜索), mpox (搜索), and measles (搜索).
According to company leadership, Anil R. Diwan, PhD, emphasized the importance of NV-387 as an effective tool against measles (搜索), particularly given the rising case numbers across the United States. The lack of approved treatments for measles positions NV-387 as a potentially significant therapeutic intervention.
Clinical Development and Technology Platform
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company's business model centers on licensing technology from TheraCour Pharma (搜索) Inc. for specific antiviral applications, established through a Memorandum of Understanding that covers all antiviral infections except cancer and similar diseases of viral origin.
The company plans to develop NV-387 as a treatment for multiple respiratory viral infections including RSV (搜索), COVID-19 (搜索), Long COVID, and influenza (搜索), in addition to mpox (搜索) and smallpox (搜索) infections. NanoViricides also maintains an advanced drug candidate, NV-HHV-1, for shingles (搜索) treatment.
Public Health Impact
With global measles (搜索) resurgence becoming a growing concern, NanoViricides suggests that NV-387 could significantly influence public health outcomes by potentially eliminating the need for quarantines and supporting economic stability. The company's nanomedicine platform represents a novel approach to antiviral therapy through special purpose nanomaterials designed for broad-spectrum viral targeting.
The orphan drug designation application comes as healthcare authorities worldwide grapple with increasing measles (搜索) transmission, making the development of effective treatments a public health priority. NanoViricides' submission represents a critical step toward addressing this unmet medical need through innovative nanomedicine technology.